Home Tags Nivolumab

Tag: Nivolumab

Conditionally Active Biologics (CAB)

Novel pH Mechanism may Enhance On-Target Effects with Reduced Off-Tumor Toxicity

The development of antibody-based immunotherapies has, compared with conventional therapeutic strategies patients, transformed the therapeutic landscape in melanoma, non-small cell lung cancer, bladder cancer,...

ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin

Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition, held virtually from December 5...

Brentuximab Vedotin in Combination with Chemotherapy Approved for Adults with Previously...

The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with chemotherapy in adult patients with previously untreated...

AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...

A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...

Nivolumab and DS-8201 to be Evaluated in HER2-Expressing Breast and Bladder...

Bristol-Myers Squibb and Daiichi Sankyo have agreed to collaborate in a clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy nivolumab (Opdivo®) and...
Featured Image: View of Lugano old town with mountains in the background, Switzerland. Courtesy: © 2017. Fotolia. Used with permission.

Combination of Brentuximab Vedotin and Nivolumab Shows 85% Objective Response Rate...

An updated interim analysis from the ongoing phase I/II clinical trial evaluating  brentuximab vedotin (Adcetris®; Seattle Gentics) and nivolumab (Opdivo®; Bristol-Myers Squibb) in relapsed...

Collaboration to Evaluate Combination of Nivolumab + Brentuximab Vedotin in Pivotal...

Bristol-Myers Squibb and Seattle Genetics have expanded their collaboration to evaluate the combination of the immunotherapy Nivolumab (Opdivo®) and the antibody-drug conjugate or ADC...

Combination of Brentuximab Vedotin + Nivolumab Shows 90% Objective Response Rate...

The first reported data from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics)  in combination with nivolumab (Opdivo; Bristol-Myers Squibb...

Collaboration to Explore the Safety and Efficacy of Combining Rova-T +...

A new Phase I/II clinical program in which Bristol-Myers Squibb collaborates with AbbVie will evaluate the safety, tolerability and efficacy of the investigational biomarker-specific...

Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...

Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...